nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—ADRA2A—type 2 diabetes mellitus	0.149	0.42	CbGaD
Nefazodone—HTR2C—type 2 diabetes mellitus	0.137	0.387	CbGaD
Nefazodone—CYP3A4—type 2 diabetes mellitus	0.0684	0.193	CbGaD
Nefazodone—ADRA1B—Bromocriptine—type 2 diabetes mellitus	0.0287	0.0734	CbGbCtD
Nefazodone—HTR2C—Bromocriptine—type 2 diabetes mellitus	0.0262	0.067	CbGbCtD
Nefazodone—HTR1A—Bromocriptine—type 2 diabetes mellitus	0.0247	0.0632	CbGbCtD
Nefazodone—ADRA2A—Bromocriptine—type 2 diabetes mellitus	0.0236	0.0604	CbGbCtD
Nefazodone—HTR2A—Bromocriptine—type 2 diabetes mellitus	0.0236	0.0604	CbGbCtD
Nefazodone—ADRA1A—Bromocriptine—type 2 diabetes mellitus	0.0226	0.0579	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Nateglinide—type 2 diabetes mellitus	0.0188	0.0482	CbGbCtD
Nefazodone—CYP3A7—Nateglinide—type 2 diabetes mellitus	0.0188	0.0482	CbGbCtD
Nefazodone—ABCB1—Linagliptin—type 2 diabetes mellitus	0.0188	0.0482	CbGbCtD
Nefazodone—ABCB1—Sitagliptin—type 2 diabetes mellitus	0.0168	0.0429	CbGbCtD
Nefazodone—CYP3A5—Nateglinide—type 2 diabetes mellitus	0.0141	0.0361	CbGbCtD
Nefazodone—ABCB1—Chlorpropamide—type 2 diabetes mellitus	0.0121	0.031	CbGbCtD
Nefazodone—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.0114	0.0292	CbGbCtD
Nefazodone—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.0113	0.0289	CbGbCtD
Nefazodone—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.0105	0.027	CbGbCtD
Nefazodone—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.01	0.0257	CbGbCtD
Nefazodone—CYP3A4—Glipizide—type 2 diabetes mellitus	0.00919	0.0235	CbGbCtD
Nefazodone—CYP3A5—Losartan—type 2 diabetes mellitus	0.00872	0.0223	CbGbCtD
Nefazodone—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.00866	0.0222	CbGbCtD
Nefazodone—ABCB1—Bromocriptine—type 2 diabetes mellitus	0.00833	0.0213	CbGbCtD
Nefazodone—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.0083	0.0212	CbGbCtD
Nefazodone—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.00803	0.0206	CbGbCtD
Nefazodone—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.00726	0.0186	CbGbCtD
Nefazodone—ABCB1—Glyburide—type 2 diabetes mellitus	0.00621	0.0159	CbGbCtD
Nefazodone—ABCB1—Losartan—type 2 diabetes mellitus	0.00568	0.0145	CbGbCtD
Nefazodone—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.00551	0.0141	CbGbCtD
Nefazodone—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.00528	0.0135	CbGbCtD
Nefazodone—CYP3A4—Orlistat—type 2 diabetes mellitus	0.00528	0.0135	CbGbCtD
Nefazodone—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.00499	0.0128	CbGbCtD
Nefazodone—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00372	0.00952	CbGbCtD
Nefazodone—CYP3A4—Losartan—type 2 diabetes mellitus	0.0034	0.00871	CbGbCtD
Nefazodone—SLC6A2—sympathetic nervous system—type 2 diabetes mellitus	0.00271	0.103	CbGeAlD
Nefazodone—HTR2A—arteriole—type 2 diabetes mellitus	0.00256	0.0976	CbGeAlD
Nefazodone—SLC6A2—autonomic nervous system—type 2 diabetes mellitus	0.00182	0.0695	CbGeAlD
Nefazodone—HTR2A—sympathetic nervous system—type 2 diabetes mellitus	0.00163	0.0622	CbGeAlD
Nefazodone—SLC6A3—nerve—type 2 diabetes mellitus	0.00127	0.0485	CbGeAlD
Nefazodone—HTR2A—autonomic nervous system—type 2 diabetes mellitus	0.0011	0.0418	CbGeAlD
Nefazodone—SLC6A2—nerve—type 2 diabetes mellitus	0.00103	0.0391	CbGeAlD
Nefazodone—HTR2A—hindlimb—type 2 diabetes mellitus	0.00101	0.0387	CbGeAlD
Nefazodone—ADRA2A—peripheral nervous system—type 2 diabetes mellitus	0.00093	0.0355	CbGeAlD
Nefazodone—HTR2A—peripheral nervous system—type 2 diabetes mellitus	0.000791	0.0302	CbGeAlD
Nefazodone—CYP3A7-CYP3A51P—nephron tubule—type 2 diabetes mellitus	0.000717	0.0273	CbGeAlD
Nefazodone—HTR2A—artery—type 2 diabetes mellitus	0.000622	0.0237	CbGeAlD
Nefazodone—HTR2A—nerve—type 2 diabetes mellitus	0.000617	0.0235	CbGeAlD
Nefazodone—CYP3A7-CYP3A51P—cortex of kidney—type 2 diabetes mellitus	0.000614	0.0234	CbGeAlD
Nefazodone—ADRA1B—kidney—type 2 diabetes mellitus	0.000582	0.0222	CbGeAlD
Nefazodone—HTR2A—endothelium—type 2 diabetes mellitus	0.000525	0.02	CbGeAlD
Nefazodone—CYP3A7—liver—type 2 diabetes mellitus	0.000468	0.0178	CbGeAlD
Nefazodone—CYP3A7-CYP3A51P—liver—type 2 diabetes mellitus	0.000398	0.0152	CbGeAlD
Nefazodone—CYP3A5—islet of Langerhans—type 2 diabetes mellitus	0.000368	0.014	CbGeAlD
Nefazodone—HTR1A—cardiovascular system—type 2 diabetes mellitus	0.000362	0.0138	CbGeAlD
Nefazodone—ADRA2A—islet of Langerhans—type 2 diabetes mellitus	0.000351	0.0134	CbGeAlD
Nefazodone—ADRA1A—cardiovascular system—type 2 diabetes mellitus	0.000334	0.0127	CbGeAlD
Nefazodone—CYP3A5—nephron tubule—type 2 diabetes mellitus	0.000297	0.0113	CbGeAlD
Nefazodone—ADRA1A—adipose tissue—type 2 diabetes mellitus	0.000295	0.0112	CbGeAlD
Nefazodone—CYP3A5—kidney—type 2 diabetes mellitus	0.000261	0.00994	CbGeAlD
Nefazodone—CYP3A5—pancreas—type 2 diabetes mellitus	0.000259	0.00987	CbGeAlD
Nefazodone—Fluphenazine—CALM1—type 2 diabetes mellitus	0.000256	0.08	CrCbGaD
Nefazodone—HTR2A—retina—type 2 diabetes mellitus	0.000255	0.00973	CbGeAlD
Nefazodone—CYP3A5—cortex of kidney—type 2 diabetes mellitus	0.000254	0.00968	CbGeAlD
Nefazodone—ADRA2A—pancreas—type 2 diabetes mellitus	0.000247	0.00941	CbGeAlD
Nefazodone—ADRA2A—cortex of kidney—type 2 diabetes mellitus	0.000242	0.00923	CbGeAlD
Nefazodone—CYP3A5—adipose tissue—type 2 diabetes mellitus	0.000235	0.00896	CbGeAlD
Nefazodone—ADRA2A—adipose tissue—type 2 diabetes mellitus	0.000224	0.00854	CbGeAlD
Nefazodone—Meclizine—CYP1A2—type 2 diabetes mellitus	0.000218	0.068	CrCbGaD
Nefazodone—HTR2A—cardiovascular system—type 2 diabetes mellitus	0.000216	0.00823	CbGeAlD
Nefazodone—HTR2A—kidney—type 2 diabetes mellitus	0.000211	0.00806	CbGeAlD
Nefazodone—ADRA1A—liver—type 2 diabetes mellitus	0.000207	0.00788	CbGeAlD
Nefazodone—Trifluoperazine—CALM1—type 2 diabetes mellitus	0.000205	0.064	CrCbGaD
Nefazodone—Perphenazine—CALM1—type 2 diabetes mellitus	0.000203	0.0633	CrCbGaD
Nefazodone—ABCB1—islet of Langerhans—type 2 diabetes mellitus	0.000196	0.00746	CbGeAlD
Nefazodone—CYP3A4—kidney—type 2 diabetes mellitus	0.000196	0.00746	CbGeAlD
Nefazodone—CYP2D6—kidney—type 2 diabetes mellitus	0.000193	0.00734	CbGeAlD
Nefazodone—ABCB1—retina—type 2 diabetes mellitus	0.000167	0.00638	CbGeAlD
Nefazodone—CYP3A5—liver—type 2 diabetes mellitus	0.000165	0.00628	CbGeAlD
Nefazodone—ABCB1—nephron tubule—type 2 diabetes mellitus	0.000158	0.00601	CbGeAlD
Nefazodone—Zuclopenthixol—ADRA2A—type 2 diabetes mellitus	0.000156	0.0486	CrCbGaD
Nefazodone—Aripiprazole—ADRA2A—type 2 diabetes mellitus	0.000144	0.0449	CrCbGaD
Nefazodone—Trazodone—ADRA2A—type 2 diabetes mellitus	0.000143	0.0447	CrCbGaD
Nefazodone—ABCB1—cardiovascular system—type 2 diabetes mellitus	0.000142	0.0054	CbGeAlD
Nefazodone—ABCB1—kidney—type 2 diabetes mellitus	0.000139	0.00528	CbGeAlD
Nefazodone—ABCB1—pancreas—type 2 diabetes mellitus	0.000138	0.00524	CbGeAlD
Nefazodone—ABCB1—cortex of kidney—type 2 diabetes mellitus	0.000135	0.00514	CbGeAlD
Nefazodone—HTR2A—liver—type 2 diabetes mellitus	0.000134	0.00509	CbGeAlD
Nefazodone—Aripiprazole—HTR2C—type 2 diabetes mellitus	0.000132	0.0414	CrCbGaD
Nefazodone—Trazodone—HTR2C—type 2 diabetes mellitus	0.000132	0.0412	CrCbGaD
Nefazodone—Domperidone—CYP1A2—type 2 diabetes mellitus	0.000129	0.0404	CrCbGaD
Nefazodone—ABCB1—adipose tissue—type 2 diabetes mellitus	0.000125	0.00476	CbGeAlD
Nefazodone—CYP3A4—liver—type 2 diabetes mellitus	0.000124	0.00471	CbGeAlD
Nefazodone—CYP2D6—liver—type 2 diabetes mellitus	0.000122	0.00464	CbGeAlD
Nefazodone—Prochlorperazine—HTR2C—type 2 diabetes mellitus	0.000118	0.0369	CrCbGaD
Nefazodone—Fluphenazine—ADRA2A—type 2 diabetes mellitus	0.000116	0.0362	CrCbGaD
Nefazodone—Fluphenazine—HTR2C—type 2 diabetes mellitus	0.000107	0.0334	CrCbGaD
Nefazodone—Perphenazine—ADRA2A—type 2 diabetes mellitus	9.17e-05	0.0286	CrCbGaD
Nefazodone—Quetiapine—ADRA2A—type 2 diabetes mellitus	9e-05	0.0281	CrCbGaD
Nefazodone—ABCB1—liver—type 2 diabetes mellitus	8.76e-05	0.00334	CbGeAlD
Nefazodone—Domperidone—CYP3A4—type 2 diabetes mellitus	8.57e-05	0.0268	CrCbGaD
Nefazodone—Trifluoperazine—HTR2C—type 2 diabetes mellitus	8.54e-05	0.0267	CrCbGaD
Nefazodone—Fluphenazine—CYP2E1—type 2 diabetes mellitus	8.47e-05	0.0265	CrCbGaD
Nefazodone—Perphenazine—HTR2C—type 2 diabetes mellitus	8.45e-05	0.0264	CrCbGaD
Nefazodone—Quetiapine—HTR2C—type 2 diabetes mellitus	8.28e-05	0.0259	CrCbGaD
Nefazodone—Fluphenazine—CYP1A2—type 2 diabetes mellitus	8.06e-05	0.0252	CrCbGaD
Nefazodone—Headache—Glimepiride—type 2 diabetes mellitus	6.87e-05	0.000449	CcSEcCtD
Nefazodone—Ill-defined disorder—Losartan—type 2 diabetes mellitus	6.86e-05	0.000448	CcSEcCtD
Nefazodone—Cough—Irbesartan—type 2 diabetes mellitus	6.86e-05	0.000448	CcSEcCtD
Nefazodone—Headache—Sitagliptin—type 2 diabetes mellitus	6.85e-05	0.000447	CcSEcCtD
Nefazodone—Anaemia—Losartan—type 2 diabetes mellitus	6.83e-05	0.000446	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	6.8e-05	0.000444	CcSEcCtD
Nefazodone—Agitation—Losartan—type 2 diabetes mellitus	6.79e-05	0.000444	CcSEcCtD
Nefazodone—Oedema—Metformin—type 2 diabetes mellitus	6.79e-05	0.000444	CcSEcCtD
Nefazodone—Tinnitus—Ramipril—type 2 diabetes mellitus	6.79e-05	0.000443	CcSEcCtD
Nefazodone—Hypertension—Irbesartan—type 2 diabetes mellitus	6.78e-05	0.000443	CcSEcCtD
Nefazodone—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	6.77e-05	0.000442	CcSEcCtD
Nefazodone—Flushing—Ramipril—type 2 diabetes mellitus	6.76e-05	0.000441	CcSEcCtD
Nefazodone—Angioedema—Losartan—type 2 diabetes mellitus	6.76e-05	0.000441	CcSEcCtD
Nefazodone—Infection—Metformin—type 2 diabetes mellitus	6.75e-05	0.000441	CcSEcCtD
Nefazodone—Insomnia—Valsartan—type 2 diabetes mellitus	6.75e-05	0.000441	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	6.72e-05	0.000439	CcSEcCtD
Nefazodone—Paraesthesia—Valsartan—type 2 diabetes mellitus	6.7e-05	0.000437	CcSEcCtD
Nefazodone—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	6.69e-05	0.000437	CcSEcCtD
Nefazodone—Chest pain—Irbesartan—type 2 diabetes mellitus	6.69e-05	0.000437	CcSEcCtD
Nefazodone—Myalgia—Irbesartan—type 2 diabetes mellitus	6.69e-05	0.000437	CcSEcCtD
Nefazodone—Arthralgia—Irbesartan—type 2 diabetes mellitus	6.69e-05	0.000437	CcSEcCtD
Nefazodone—Shock—Metformin—type 2 diabetes mellitus	6.68e-05	0.000436	CcSEcCtD
Nefazodone—Insomnia—Orlistat—type 2 diabetes mellitus	6.67e-05	0.000435	CcSEcCtD
Nefazodone—Malaise—Losartan—type 2 diabetes mellitus	6.67e-05	0.000435	CcSEcCtD
Nefazodone—Anxiety—Irbesartan—type 2 diabetes mellitus	6.67e-05	0.000435	CcSEcCtD
Nefazodone—Hypersensitivity—Glyburide—type 2 diabetes mellitus	6.66e-05	0.000435	CcSEcCtD
Nefazodone—Thrombocytopenia—Metformin—type 2 diabetes mellitus	6.65e-05	0.000434	CcSEcCtD
Nefazodone—Dyspnoea—Valsartan—type 2 diabetes mellitus	6.65e-05	0.000434	CcSEcCtD
Nefazodone—Vertigo—Losartan—type 2 diabetes mellitus	6.64e-05	0.000434	CcSEcCtD
Nefazodone—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	6.64e-05	0.000434	CcSEcCtD
Nefazodone—Somnolence—Valsartan—type 2 diabetes mellitus	6.63e-05	0.000433	CcSEcCtD
Nefazodone—Syncope—Losartan—type 2 diabetes mellitus	6.63e-05	0.000433	CcSEcCtD
Nefazodone—Paraesthesia—Orlistat—type 2 diabetes mellitus	6.62e-05	0.000432	CcSEcCtD
Nefazodone—Aripiprazole—CYP3A4—type 2 diabetes mellitus	6.62e-05	0.0207	CrCbGaD
Nefazodone—Leukopenia—Losartan—type 2 diabetes mellitus	6.62e-05	0.000432	CcSEcCtD
Nefazodone—Discomfort—Irbesartan—type 2 diabetes mellitus	6.61e-05	0.000432	CcSEcCtD
Nefazodone—Trazodone—CYP3A4—type 2 diabetes mellitus	6.59e-05	0.0206	CrCbGaD
Nefazodone—Hyperhidrosis—Metformin—type 2 diabetes mellitus	6.57e-05	0.000429	CcSEcCtD
Nefazodone—Dyspepsia—Valsartan—type 2 diabetes mellitus	6.57e-05	0.000429	CcSEcCtD
Nefazodone—Dizziness—Bromocriptine—type 2 diabetes mellitus	6.54e-05	0.000427	CcSEcCtD
Nefazodone—Dry mouth—Irbesartan—type 2 diabetes mellitus	6.54e-05	0.000427	CcSEcCtD
Nefazodone—Palpitations—Losartan—type 2 diabetes mellitus	6.53e-05	0.000427	CcSEcCtD
Nefazodone—Nausea—Glimepiride—type 2 diabetes mellitus	6.51e-05	0.000425	CcSEcCtD
Nefazodone—Loss of consciousness—Losartan—type 2 diabetes mellitus	6.5e-05	0.000424	CcSEcCtD
Nefazodone—Nausea—Sitagliptin—type 2 diabetes mellitus	6.49e-05	0.000424	CcSEcCtD
Nefazodone—Dyspepsia—Orlistat—type 2 diabetes mellitus	6.49e-05	0.000424	CcSEcCtD
Nefazodone—Asthenia—Glyburide—type 2 diabetes mellitus	6.49e-05	0.000424	CcSEcCtD
Nefazodone—Decreased appetite—Valsartan—type 2 diabetes mellitus	6.49e-05	0.000424	CcSEcCtD
Nefazodone—Anorexia—Metformin—type 2 diabetes mellitus	6.48e-05	0.000423	CcSEcCtD
Nefazodone—Cough—Losartan—type 2 diabetes mellitus	6.45e-05	0.000421	CcSEcCtD
Nefazodone—Urticaria—Gliclazide—type 2 diabetes mellitus	6.45e-05	0.000421	CcSEcCtD
Nefazodone—Trifluoperazine—CYP1A2—type 2 diabetes mellitus	6.44e-05	0.0201	CrCbGaD
Nefazodone—Alopecia—Ramipril—type 2 diabetes mellitus	6.44e-05	0.00042	CcSEcCtD
Nefazodone—Abdominal pain—Gliclazide—type 2 diabetes mellitus	6.42e-05	0.000419	CcSEcCtD
Nefazodone—Body temperature increased—Gliclazide—type 2 diabetes mellitus	6.42e-05	0.000419	CcSEcCtD
Nefazodone—Oedema—Irbesartan—type 2 diabetes mellitus	6.41e-05	0.000419	CcSEcCtD
Nefazodone—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	6.41e-05	0.000419	CcSEcCtD
Nefazodone—Decreased appetite—Orlistat—type 2 diabetes mellitus	6.41e-05	0.000418	CcSEcCtD
Nefazodone—Pruritus—Glyburide—type 2 diabetes mellitus	6.4e-05	0.000418	CcSEcCtD
Nefazodone—Constipation—Valsartan—type 2 diabetes mellitus	6.38e-05	0.000417	CcSEcCtD
Nefazodone—Perphenazine—CYP1A2—type 2 diabetes mellitus	6.37e-05	0.0199	CrCbGaD
Nefazodone—Infection—Irbesartan—type 2 diabetes mellitus	6.37e-05	0.000416	CcSEcCtD
Nefazodone—Hypotension—Metformin—type 2 diabetes mellitus	6.35e-05	0.000415	CcSEcCtD
Nefazodone—Shock—Irbesartan—type 2 diabetes mellitus	6.31e-05	0.000412	CcSEcCtD
Nefazodone—Pain—Orlistat—type 2 diabetes mellitus	6.3e-05	0.000412	CcSEcCtD
Nefazodone—Myalgia—Losartan—type 2 diabetes mellitus	6.29e-05	0.000411	CcSEcCtD
Nefazodone—Arthralgia—Losartan—type 2 diabetes mellitus	6.29e-05	0.000411	CcSEcCtD
Nefazodone—Chest pain—Losartan—type 2 diabetes mellitus	6.29e-05	0.000411	CcSEcCtD
Nefazodone—Vomiting—Bromocriptine—type 2 diabetes mellitus	6.29e-05	0.000411	CcSEcCtD
Nefazodone—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	6.28e-05	0.00041	CcSEcCtD
Nefazodone—Anxiety—Losartan—type 2 diabetes mellitus	6.27e-05	0.00041	CcSEcCtD
Nefazodone—Tachycardia—Irbesartan—type 2 diabetes mellitus	6.26e-05	0.000409	CcSEcCtD
Nefazodone—Rash—Bromocriptine—type 2 diabetes mellitus	6.24e-05	0.000407	CcSEcCtD
Nefazodone—Dermatitis—Bromocriptine—type 2 diabetes mellitus	6.23e-05	0.000407	CcSEcCtD
Nefazodone—Discomfort—Losartan—type 2 diabetes mellitus	6.22e-05	0.000406	CcSEcCtD
Nefazodone—Dysgeusia—Ramipril—type 2 diabetes mellitus	6.21e-05	0.000405	CcSEcCtD
Nefazodone—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	6.2e-05	0.000405	CcSEcCtD
Nefazodone—Headache—Bromocriptine—type 2 diabetes mellitus	6.2e-05	0.000405	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	6.19e-05	0.000404	CcSEcCtD
Nefazodone—Diarrhoea—Glyburide—type 2 diabetes mellitus	6.19e-05	0.000404	CcSEcCtD
Nefazodone—Dry mouth—Losartan—type 2 diabetes mellitus	6.16e-05	0.000402	CcSEcCtD
Nefazodone—Anorexia—Irbesartan—type 2 diabetes mellitus	6.11e-05	0.000399	CcSEcCtD
Nefazodone—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	6.1e-05	0.000398	CcSEcCtD
Nefazodone—Paraesthesia—Metformin—type 2 diabetes mellitus	6.1e-05	0.000398	CcSEcCtD
Nefazodone—Muscle spasms—Ramipril—type 2 diabetes mellitus	6.1e-05	0.000398	CcSEcCtD
Nefazodone—Confusional state—Losartan—type 2 diabetes mellitus	6.08e-05	0.000397	CcSEcCtD
Nefazodone—Feeling abnormal—Orlistat—type 2 diabetes mellitus	6.08e-05	0.000397	CcSEcCtD
Nefazodone—Dyspnoea—Metformin—type 2 diabetes mellitus	6.06e-05	0.000396	CcSEcCtD
Nefazodone—Somnolence—Metformin—type 2 diabetes mellitus	6.04e-05	0.000394	CcSEcCtD
Nefazodone—Anaphylactic shock—Losartan—type 2 diabetes mellitus	6.03e-05	0.000394	CcSEcCtD
Nefazodone—Oedema—Losartan—type 2 diabetes mellitus	6.03e-05	0.000394	CcSEcCtD
Nefazodone—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	6.03e-05	0.000394	CcSEcCtD
Nefazodone—Infection—Losartan—type 2 diabetes mellitus	5.99e-05	0.000391	CcSEcCtD
Nefazodone—Hypotension—Irbesartan—type 2 diabetes mellitus	5.99e-05	0.000391	CcSEcCtD
Nefazodone—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	5.98e-05	0.000391	CcSEcCtD
Nefazodone—Dyspepsia—Metformin—type 2 diabetes mellitus	5.98e-05	0.000391	CcSEcCtD
Nefazodone—Tremor—Ramipril—type 2 diabetes mellitus	5.94e-05	0.000388	CcSEcCtD
Nefazodone—Shock—Losartan—type 2 diabetes mellitus	5.94e-05	0.000388	CcSEcCtD
Nefazodone—Urticaria—Valsartan—type 2 diabetes mellitus	5.93e-05	0.000387	CcSEcCtD
Nefazodone—Thrombocytopenia—Losartan—type 2 diabetes mellitus	5.91e-05	0.000386	CcSEcCtD
Nefazodone—Decreased appetite—Metformin—type 2 diabetes mellitus	5.91e-05	0.000386	CcSEcCtD
Nefazodone—Prochlorperazine—CYP3A4—type 2 diabetes mellitus	5.9e-05	0.0184	CrCbGaD
Nefazodone—Abdominal pain—Valsartan—type 2 diabetes mellitus	5.9e-05	0.000385	CcSEcCtD
Nefazodone—Tachycardia—Losartan—type 2 diabetes mellitus	5.89e-05	0.000385	CcSEcCtD
Nefazodone—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	5.88e-05	0.000384	CcSEcCtD
Nefazodone—Nausea—Bromocriptine—type 2 diabetes mellitus	5.88e-05	0.000384	CcSEcCtD
Nefazodone—Urticaria—Orlistat—type 2 diabetes mellitus	5.86e-05	0.000382	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	5.84e-05	0.000381	CcSEcCtD
Nefazodone—Hyperhidrosis—Losartan—type 2 diabetes mellitus	5.83e-05	0.000381	CcSEcCtD
Nefazodone—Abdominal pain—Orlistat—type 2 diabetes mellitus	5.83e-05	0.000381	CcSEcCtD
Nefazodone—Body temperature increased—Orlistat—type 2 diabetes mellitus	5.83e-05	0.000381	CcSEcCtD
Nefazodone—Asthenia—Gliclazide—type 2 diabetes mellitus	5.83e-05	0.00038	CcSEcCtD
Nefazodone—Agitation—Ramipril—type 2 diabetes mellitus	5.83e-05	0.00038	CcSEcCtD
Nefazodone—Constipation—Metformin—type 2 diabetes mellitus	5.81e-05	0.000379	CcSEcCtD
Nefazodone—Angioedema—Ramipril—type 2 diabetes mellitus	5.79e-05	0.000378	CcSEcCtD
Nefazodone—Paraesthesia—Irbesartan—type 2 diabetes mellitus	5.76e-05	0.000376	CcSEcCtD
Nefazodone—Anorexia—Losartan—type 2 diabetes mellitus	5.75e-05	0.000376	CcSEcCtD
Nefazodone—Vomiting—Glyburide—type 2 diabetes mellitus	5.75e-05	0.000375	CcSEcCtD
Nefazodone—Pruritus—Gliclazide—type 2 diabetes mellitus	5.75e-05	0.000375	CcSEcCtD
Nefazodone—Malaise—Ramipril—type 2 diabetes mellitus	5.72e-05	0.000373	CcSEcCtD
Nefazodone—Dyspnoea—Irbesartan—type 2 diabetes mellitus	5.72e-05	0.000373	CcSEcCtD
Nefazodone—Rash—Glyburide—type 2 diabetes mellitus	5.7e-05	0.000372	CcSEcCtD
Nefazodone—Somnolence—Irbesartan—type 2 diabetes mellitus	5.7e-05	0.000372	CcSEcCtD
Nefazodone—Dermatitis—Glyburide—type 2 diabetes mellitus	5.7e-05	0.000372	CcSEcCtD
Nefazodone—Vertigo—Ramipril—type 2 diabetes mellitus	5.7e-05	0.000372	CcSEcCtD
Nefazodone—Syncope—Ramipril—type 2 diabetes mellitus	5.69e-05	0.000371	CcSEcCtD
Nefazodone—Leukopenia—Ramipril—type 2 diabetes mellitus	5.67e-05	0.000371	CcSEcCtD
Nefazodone—Headache—Glyburide—type 2 diabetes mellitus	5.67e-05	0.00037	CcSEcCtD
Nefazodone—Dyspepsia—Irbesartan—type 2 diabetes mellitus	5.64e-05	0.000369	CcSEcCtD
Nefazodone—Hypotension—Losartan—type 2 diabetes mellitus	5.64e-05	0.000368	CcSEcCtD
Nefazodone—Palpitations—Ramipril—type 2 diabetes mellitus	5.6e-05	0.000366	CcSEcCtD
Nefazodone—Feeling abnormal—Metformin—type 2 diabetes mellitus	5.6e-05	0.000366	CcSEcCtD
Nefazodone—Decreased appetite—Irbesartan—type 2 diabetes mellitus	5.57e-05	0.000364	CcSEcCtD
Nefazodone—Loss of consciousness—Ramipril—type 2 diabetes mellitus	5.57e-05	0.000364	CcSEcCtD
Nefazodone—Diarrhoea—Gliclazide—type 2 diabetes mellitus	5.56e-05	0.000363	CcSEcCtD
Nefazodone—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	5.56e-05	0.000363	CcSEcCtD
Nefazodone—Cough—Ramipril—type 2 diabetes mellitus	5.53e-05	0.000361	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	5.5e-05	0.000359	CcSEcCtD
Nefazodone—Hypersensitivity—Valsartan—type 2 diabetes mellitus	5.5e-05	0.000359	CcSEcCtD
Nefazodone—Convulsion—Ramipril—type 2 diabetes mellitus	5.49e-05	0.000359	CcSEcCtD
Nefazodone—Pain—Irbesartan—type 2 diabetes mellitus	5.48e-05	0.000358	CcSEcCtD
Nefazodone—Constipation—Irbesartan—type 2 diabetes mellitus	5.48e-05	0.000358	CcSEcCtD
Nefazodone—Thioproperazine—ALB—type 2 diabetes mellitus	5.47e-05	0.0171	CrCbGaD
Nefazodone—Insomnia—Losartan—type 2 diabetes mellitus	5.46e-05	0.000356	CcSEcCtD
Nefazodone—Hypersensitivity—Orlistat—type 2 diabetes mellitus	5.43e-05	0.000355	CcSEcCtD
Nefazodone—Paraesthesia—Losartan—type 2 diabetes mellitus	5.42e-05	0.000354	CcSEcCtD
Nefazodone—Urticaria—Metformin—type 2 diabetes mellitus	5.4e-05	0.000352	CcSEcCtD
Nefazodone—Arthralgia—Ramipril—type 2 diabetes mellitus	5.4e-05	0.000352	CcSEcCtD
Nefazodone—Chest pain—Ramipril—type 2 diabetes mellitus	5.4e-05	0.000352	CcSEcCtD
Nefazodone—Myalgia—Ramipril—type 2 diabetes mellitus	5.4e-05	0.000352	CcSEcCtD
Nefazodone—Dyspnoea—Losartan—type 2 diabetes mellitus	5.38e-05	0.000351	CcSEcCtD
Nefazodone—Anxiety—Ramipril—type 2 diabetes mellitus	5.38e-05	0.000351	CcSEcCtD
Nefazodone—Nausea—Glyburide—type 2 diabetes mellitus	5.37e-05	0.000351	CcSEcCtD
Nefazodone—Abdominal pain—Metformin—type 2 diabetes mellitus	5.37e-05	0.000351	CcSEcCtD
Nefazodone—Dizziness—Gliclazide—type 2 diabetes mellitus	5.37e-05	0.000351	CcSEcCtD
Nefazodone—Somnolence—Losartan—type 2 diabetes mellitus	5.36e-05	0.00035	CcSEcCtD
Nefazodone—Asthenia—Valsartan—type 2 diabetes mellitus	5.35e-05	0.00035	CcSEcCtD
Nefazodone—Discomfort—Ramipril—type 2 diabetes mellitus	5.33e-05	0.000348	CcSEcCtD
Nefazodone—Dyspepsia—Losartan—type 2 diabetes mellitus	5.31e-05	0.000347	CcSEcCtD
Nefazodone—Asthenia—Orlistat—type 2 diabetes mellitus	5.29e-05	0.000345	CcSEcCtD
Nefazodone—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	5.28e-05	0.000345	CcSEcCtD
Nefazodone—Pruritus—Valsartan—type 2 diabetes mellitus	5.28e-05	0.000345	CcSEcCtD
Nefazodone—Dry mouth—Ramipril—type 2 diabetes mellitus	5.28e-05	0.000345	CcSEcCtD
Nefazodone—Decreased appetite—Losartan—type 2 diabetes mellitus	5.25e-05	0.000343	CcSEcCtD
Nefazodone—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	5.24e-05	0.000342	CcSEcCtD
Nefazodone—Confusional state—Ramipril—type 2 diabetes mellitus	5.22e-05	0.000341	CcSEcCtD
Nefazodone—Pruritus—Orlistat—type 2 diabetes mellitus	5.22e-05	0.000341	CcSEcCtD
Nefazodone—Oedema—Ramipril—type 2 diabetes mellitus	5.17e-05	0.000338	CcSEcCtD
Nefazodone—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	5.17e-05	0.000338	CcSEcCtD
Nefazodone—Vomiting—Gliclazide—type 2 diabetes mellitus	5.16e-05	0.000337	CcSEcCtD
Nefazodone—Pain—Losartan—type 2 diabetes mellitus	5.16e-05	0.000337	CcSEcCtD
Nefazodone—Constipation—Losartan—type 2 diabetes mellitus	5.16e-05	0.000337	CcSEcCtD
Nefazodone—Rash—Gliclazide—type 2 diabetes mellitus	5.12e-05	0.000334	CcSEcCtD
Nefazodone—Dermatitis—Gliclazide—type 2 diabetes mellitus	5.12e-05	0.000334	CcSEcCtD
Nefazodone—Diarrhoea—Valsartan—type 2 diabetes mellitus	5.1e-05	0.000333	CcSEcCtD
Nefazodone—Urticaria—Irbesartan—type 2 diabetes mellitus	5.09e-05	0.000333	CcSEcCtD
Nefazodone—Shock—Ramipril—type 2 diabetes mellitus	5.09e-05	0.000332	CcSEcCtD
Nefazodone—Headache—Gliclazide—type 2 diabetes mellitus	5.09e-05	0.000332	CcSEcCtD
Nefazodone—Abdominal pain—Irbesartan—type 2 diabetes mellitus	5.07e-05	0.000331	CcSEcCtD
Nefazodone—Body temperature increased—Irbesartan—type 2 diabetes mellitus	5.07e-05	0.000331	CcSEcCtD
Nefazodone—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	5.07e-05	0.000331	CcSEcCtD
Nefazodone—Tachycardia—Ramipril—type 2 diabetes mellitus	5.05e-05	0.00033	CcSEcCtD
Nefazodone—Diarrhoea—Orlistat—type 2 diabetes mellitus	5.04e-05	0.000329	CcSEcCtD
Nefazodone—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	5e-05	0.000327	CcSEcCtD
Nefazodone—Feeling abnormal—Losartan—type 2 diabetes mellitus	4.97e-05	0.000325	CcSEcCtD
Nefazodone—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	4.93e-05	0.000322	CcSEcCtD
Nefazodone—Dizziness—Valsartan—type 2 diabetes mellitus	4.93e-05	0.000322	CcSEcCtD
Nefazodone—Anorexia—Ramipril—type 2 diabetes mellitus	4.93e-05	0.000322	CcSEcCtD
Nefazodone—Dizziness—Orlistat—type 2 diabetes mellitus	4.88e-05	0.000318	CcSEcCtD
Nefazodone—Asthenia—Metformin—type 2 diabetes mellitus	4.87e-05	0.000318	CcSEcCtD
Nefazodone—Hypotension—Ramipril—type 2 diabetes mellitus	4.83e-05	0.000316	CcSEcCtD
Nefazodone—Nausea—Gliclazide—type 2 diabetes mellitus	4.82e-05	0.000315	CcSEcCtD
Nefazodone—Pruritus—Metformin—type 2 diabetes mellitus	4.81e-05	0.000314	CcSEcCtD
Nefazodone—Urticaria—Losartan—type 2 diabetes mellitus	4.79e-05	0.000313	CcSEcCtD
Nefazodone—Abdominal pain—Losartan—type 2 diabetes mellitus	4.77e-05	0.000311	CcSEcCtD
Nefazodone—Body temperature increased—Losartan—type 2 diabetes mellitus	4.77e-05	0.000311	CcSEcCtD
Nefazodone—Vomiting—Valsartan—type 2 diabetes mellitus	4.74e-05	0.00031	CcSEcCtD
Nefazodone—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	4.72e-05	0.000308	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	4.71e-05	0.000308	CcSEcCtD
Nefazodone—Rash—Valsartan—type 2 diabetes mellitus	4.7e-05	0.000307	CcSEcCtD
Nefazodone—Dermatitis—Valsartan—type 2 diabetes mellitus	4.7e-05	0.000307	CcSEcCtD
Nefazodone—Vomiting—Orlistat—type 2 diabetes mellitus	4.69e-05	0.000306	CcSEcCtD
Nefazodone—Insomnia—Ramipril—type 2 diabetes mellitus	4.68e-05	0.000306	CcSEcCtD
Nefazodone—Headache—Valsartan—type 2 diabetes mellitus	4.67e-05	0.000305	CcSEcCtD
Nefazodone—Diarrhoea—Metformin—type 2 diabetes mellitus	4.65e-05	0.000304	CcSEcCtD
Nefazodone—Rash—Orlistat—type 2 diabetes mellitus	4.65e-05	0.000304	CcSEcCtD
Nefazodone—Paraesthesia—Ramipril—type 2 diabetes mellitus	4.65e-05	0.000303	CcSEcCtD
Nefazodone—Dermatitis—Orlistat—type 2 diabetes mellitus	4.64e-05	0.000303	CcSEcCtD
Nefazodone—Headache—Orlistat—type 2 diabetes mellitus	4.62e-05	0.000302	CcSEcCtD
Nefazodone—Dyspnoea—Ramipril—type 2 diabetes mellitus	4.61e-05	0.000301	CcSEcCtD
Nefazodone—Asthenia—Irbesartan—type 2 diabetes mellitus	4.6e-05	0.0003	CcSEcCtD
Nefazodone—Somnolence—Ramipril—type 2 diabetes mellitus	4.6e-05	0.0003	CcSEcCtD
Nefazodone—Dyspepsia—Ramipril—type 2 diabetes mellitus	4.55e-05	0.000297	CcSEcCtD
Nefazodone—Pruritus—Irbesartan—type 2 diabetes mellitus	4.54e-05	0.000296	CcSEcCtD
Nefazodone—Decreased appetite—Ramipril—type 2 diabetes mellitus	4.5e-05	0.000294	CcSEcCtD
Nefazodone—Dizziness—Metformin—type 2 diabetes mellitus	4.49e-05	0.000293	CcSEcCtD
Nefazodone—Hypersensitivity—Losartan—type 2 diabetes mellitus	4.45e-05	0.00029	CcSEcCtD
Nefazodone—Nausea—Valsartan—type 2 diabetes mellitus	4.43e-05	0.000289	CcSEcCtD
Nefazodone—Constipation—Ramipril—type 2 diabetes mellitus	4.42e-05	0.000289	CcSEcCtD
Nefazodone—Diarrhoea—Irbesartan—type 2 diabetes mellitus	4.39e-05	0.000286	CcSEcCtD
Nefazodone—Nausea—Orlistat—type 2 diabetes mellitus	4.38e-05	0.000286	CcSEcCtD
Nefazodone—Asthenia—Losartan—type 2 diabetes mellitus	4.33e-05	0.000283	CcSEcCtD
Nefazodone—Vomiting—Metformin—type 2 diabetes mellitus	4.32e-05	0.000282	CcSEcCtD
Nefazodone—Rash—Metformin—type 2 diabetes mellitus	4.28e-05	0.00028	CcSEcCtD
Nefazodone—Dermatitis—Metformin—type 2 diabetes mellitus	4.28e-05	0.000279	CcSEcCtD
Nefazodone—Pruritus—Losartan—type 2 diabetes mellitus	4.27e-05	0.000279	CcSEcCtD
Nefazodone—Feeling abnormal—Ramipril—type 2 diabetes mellitus	4.26e-05	0.000278	CcSEcCtD
Nefazodone—Headache—Metformin—type 2 diabetes mellitus	4.26e-05	0.000278	CcSEcCtD
Nefazodone—Dizziness—Irbesartan—type 2 diabetes mellitus	4.24e-05	0.000277	CcSEcCtD
Nefazodone—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	4.23e-05	0.000276	CcSEcCtD
Nefazodone—Perphenazine—CYP3A4—type 2 diabetes mellitus	4.22e-05	0.0132	CrCbGaD
Nefazodone—Quetiapine—CYP3A4—type 2 diabetes mellitus	4.14e-05	0.0129	CrCbGaD
Nefazodone—Diarrhoea—Losartan—type 2 diabetes mellitus	4.13e-05	0.00027	CcSEcCtD
Nefazodone—Urticaria—Ramipril—type 2 diabetes mellitus	4.11e-05	0.000268	CcSEcCtD
Nefazodone—Abdominal pain—Ramipril—type 2 diabetes mellitus	4.09e-05	0.000267	CcSEcCtD
Nefazodone—Body temperature increased—Ramipril—type 2 diabetes mellitus	4.09e-05	0.000267	CcSEcCtD
Nefazodone—Vomiting—Irbesartan—type 2 diabetes mellitus	4.08e-05	0.000266	CcSEcCtD
Nefazodone—Rash—Irbesartan—type 2 diabetes mellitus	4.04e-05	0.000264	CcSEcCtD
Nefazodone—Dermatitis—Irbesartan—type 2 diabetes mellitus	4.04e-05	0.000264	CcSEcCtD
Nefazodone—Nausea—Metformin—type 2 diabetes mellitus	4.04e-05	0.000264	CcSEcCtD
Nefazodone—Headache—Irbesartan—type 2 diabetes mellitus	4.02e-05	0.000262	CcSEcCtD
Nefazodone—Dizziness—Losartan—type 2 diabetes mellitus	3.99e-05	0.000261	CcSEcCtD
Nefazodone—Vomiting—Losartan—type 2 diabetes mellitus	3.84e-05	0.000251	CcSEcCtD
Nefazodone—Hypersensitivity—Ramipril—type 2 diabetes mellitus	3.81e-05	0.000249	CcSEcCtD
Nefazodone—Nausea—Irbesartan—type 2 diabetes mellitus	3.81e-05	0.000249	CcSEcCtD
Nefazodone—Rash—Losartan—type 2 diabetes mellitus	3.8e-05	0.000248	CcSEcCtD
Nefazodone—Dermatitis—Losartan—type 2 diabetes mellitus	3.8e-05	0.000248	CcSEcCtD
Nefazodone—Headache—Losartan—type 2 diabetes mellitus	3.78e-05	0.000247	CcSEcCtD
Nefazodone—Asthenia—Ramipril—type 2 diabetes mellitus	3.71e-05	0.000242	CcSEcCtD
Nefazodone—Pruritus—Ramipril—type 2 diabetes mellitus	3.66e-05	0.000239	CcSEcCtD
Nefazodone—Nausea—Losartan—type 2 diabetes mellitus	3.58e-05	0.000234	CcSEcCtD
Nefazodone—Diarrhoea—Ramipril—type 2 diabetes mellitus	3.54e-05	0.000231	CcSEcCtD
Nefazodone—Dizziness—Ramipril—type 2 diabetes mellitus	3.42e-05	0.000223	CcSEcCtD
Nefazodone—Vomiting—Ramipril—type 2 diabetes mellitus	3.29e-05	0.000215	CcSEcCtD
Nefazodone—Rash—Ramipril—type 2 diabetes mellitus	3.26e-05	0.000213	CcSEcCtD
Nefazodone—Dermatitis—Ramipril—type 2 diabetes mellitus	3.26e-05	0.000213	CcSEcCtD
Nefazodone—Headache—Ramipril—type 2 diabetes mellitus	3.24e-05	0.000212	CcSEcCtD
Nefazodone—Nausea—Ramipril—type 2 diabetes mellitus	3.07e-05	0.000201	CcSEcCtD
Nefazodone—ADRA1A—Signaling Pathways—CALM1—type 2 diabetes mellitus	2.92e-06	4.03e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—HMOX1—type 2 diabetes mellitus	2.92e-06	4.03e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—LEP—type 2 diabetes mellitus	2.91e-06	4.02e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—APOE—type 2 diabetes mellitus	2.91e-06	4.02e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—C3—type 2 diabetes mellitus	2.9e-06	4.01e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.89e-06	3.99e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CAT—type 2 diabetes mellitus	2.88e-06	3.97e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—APOA1—type 2 diabetes mellitus	2.88e-06	3.97e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.88e-06	3.97e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.84e-06	3.92e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.84e-06	3.92e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	2.83e-06	3.9e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.83e-06	3.9e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.83e-06	3.9e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	2.82e-06	3.89e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PPARG—type 2 diabetes mellitus	2.82e-06	3.89e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—EGFR—type 2 diabetes mellitus	2.81e-06	3.88e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PTGS2—type 2 diabetes mellitus	2.81e-06	3.88e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	2.8e-06	3.87e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—INS—type 2 diabetes mellitus	2.8e-06	3.86e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—APOB—type 2 diabetes mellitus	2.79e-06	3.86e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	2.77e-06	3.82e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	2.76e-06	3.82e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	2.76e-06	3.82e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IRS2—type 2 diabetes mellitus	2.76e-06	3.81e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—INS—type 2 diabetes mellitus	2.76e-06	3.81e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PPARGC1A—type 2 diabetes mellitus	2.76e-06	3.81e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GNB3—type 2 diabetes mellitus	2.76e-06	3.81e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—AGT—type 2 diabetes mellitus	2.76e-06	3.81e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.75e-06	3.8e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—HMOX1—type 2 diabetes mellitus	2.75e-06	3.79e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—AKT1—type 2 diabetes mellitus	2.75e-06	3.79e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	2.74e-06	3.79e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GSTM1—type 2 diabetes mellitus	2.72e-06	3.75e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CALM1—type 2 diabetes mellitus	2.71e-06	3.75e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CAT—type 2 diabetes mellitus	2.71e-06	3.74e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	2.71e-06	3.74e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.71e-06	3.74e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.71e-06	3.73e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—APOE—type 2 diabetes mellitus	2.7e-06	3.73e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—LEP—type 2 diabetes mellitus	2.7e-06	3.73e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.7e-06	3.73e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—EGFR—type 2 diabetes mellitus	2.69e-06	3.72e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	2.69e-06	3.72e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	2.69e-06	3.72e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	2.69e-06	3.72e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.69e-06	3.71e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	2.68e-06	3.69e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—APOA1—type 2 diabetes mellitus	2.67e-06	3.69e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—LPL—type 2 diabetes mellitus	2.67e-06	3.68e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IRS1—type 2 diabetes mellitus	2.65e-06	3.66e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—APOB—type 2 diabetes mellitus	2.63e-06	3.63e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	2.63e-06	3.63e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—ADCY5—type 2 diabetes mellitus	2.61e-06	3.61e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GPX1—type 2 diabetes mellitus	2.6e-06	3.59e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	2.6e-06	3.59e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IRS1—type 2 diabetes mellitus	2.6e-06	3.58e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PPARG—type 2 diabetes mellitus	2.58e-06	3.56e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.58e-06	3.56e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.58e-06	3.56e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.57e-06	3.55e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.56e-06	3.54e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.56e-06	3.54e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GSTM1—type 2 diabetes mellitus	2.56e-06	3.54e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	2.55e-06	3.52e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—INS—type 2 diabetes mellitus	2.54e-06	3.51e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CD36—type 2 diabetes mellitus	2.54e-06	3.5e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—ALB—type 2 diabetes mellitus	2.53e-06	3.5e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—INS—type 2 diabetes mellitus	2.53e-06	3.49e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—LPL—type 2 diabetes mellitus	2.51e-06	3.47e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PPP2CA—type 2 diabetes mellitus	2.5e-06	3.46e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.5e-06	3.45e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—INS—type 2 diabetes mellitus	2.49e-06	3.43e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—ADCY5—type 2 diabetes mellitus	2.46e-06	3.4e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.46e-06	3.39e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.45e-06	3.39e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.45e-06	3.39e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.45e-06	3.39e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GPX1—type 2 diabetes mellitus	2.45e-06	3.39e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.45e-06	3.38e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	2.44e-06	3.37e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—RELA—type 2 diabetes mellitus	2.43e-06	3.35e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—NOS3—type 2 diabetes mellitus	2.42e-06	3.34e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PIK3R1—type 2 diabetes mellitus	2.42e-06	3.34e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	2.42e-06	3.33e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	2.42e-06	3.33e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	2.42e-06	3.33e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—RELA—type 2 diabetes mellitus	2.41e-06	3.33e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IRS1—type 2 diabetes mellitus	2.41e-06	3.33e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.41e-06	3.32e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.4e-06	3.32e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—MTHFR—type 2 diabetes mellitus	2.4e-06	3.32e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	2.39e-06	3.3e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CD36—type 2 diabetes mellitus	2.39e-06	3.3e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	2.37e-06	3.27e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PPP2CA—type 2 diabetes mellitus	2.36e-06	3.26e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PPARA—type 2 diabetes mellitus	2.36e-06	3.25e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	2.35e-06	3.24e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.33e-06	3.22e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—ALB—type 2 diabetes mellitus	2.32e-06	3.2e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—RELA—type 2 diabetes mellitus	2.31e-06	3.19e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—INS—type 2 diabetes mellitus	2.31e-06	3.19e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	2.3e-06	3.17e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.28e-06	3.15e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—AGT—type 2 diabetes mellitus	2.28e-06	3.15e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.27e-06	3.14e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	2.26e-06	3.12e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CALM1—type 2 diabetes mellitus	2.24e-06	3.1e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—APOE—type 2 diabetes mellitus	2.24e-06	3.09e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.23e-06	3.08e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.23e-06	3.08e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.23e-06	3.07e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.23e-06	3.07e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	2.22e-06	3.07e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	2.22e-06	3.07e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PIK3R1—type 2 diabetes mellitus	2.22e-06	3.06e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—NOS3—type 2 diabetes mellitus	2.22e-06	3.06e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PTGS2—type 2 diabetes mellitus	2.22e-06	3.06e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—APOA1—type 2 diabetes mellitus	2.21e-06	3.05e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	2.21e-06	3.05e-05	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.21e-06	3.05e-05	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.2e-06	3.03e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.19e-06	3.02e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	2.19e-06	3.02e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	2.19e-06	3.02e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.18e-06	3.01e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.18e-06	3.01e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.18e-06	3.01e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.17e-06	3e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.16e-06	2.99e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	2.15e-06	2.97e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.12e-06	2.93e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	2.11e-06	2.92e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	2.11e-06	2.91e-05	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.1e-06	2.9e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—RELA—type 2 diabetes mellitus	2.1e-06	2.89e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	2.09e-06	2.89e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	2.09e-06	2.89e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.08e-06	2.88e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	2.08e-06	2.88e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.07e-06	2.86e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.07e-06	2.85e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.06e-06	2.84e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—RELA—type 2 diabetes mellitus	2.05e-06	2.83e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.05e-06	2.82e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.04e-06	2.81e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PTGS2—type 2 diabetes mellitus	2.03e-06	2.8e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.03e-06	2.8e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.03e-06	2.8e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.01e-06	2.77e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2e-06	2.75e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.97e-06	2.72e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.95e-06	2.69e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PPARG—type 2 diabetes mellitus	1.95e-06	2.69e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—INS—type 2 diabetes mellitus	1.91e-06	2.64e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.91e-06	2.64e-05	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.91e-06	2.63e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—RELA—type 2 diabetes mellitus	1.91e-06	2.63e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—SRC—type 2 diabetes mellitus	1.91e-06	2.63e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—SRC—type 2 diabetes mellitus	1.9e-06	2.62e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.89e-06	2.61e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.88e-06	2.59e-05	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.87e-06	2.58e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.86e-06	2.56e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.85e-06	2.56e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.85e-06	2.55e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.84e-06	2.54e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	1.84e-06	2.53e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—SRC—type 2 diabetes mellitus	1.82e-06	2.51e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	1.81e-06	2.49e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.81e-06	2.49e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	1.8e-06	2.49e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	1.8e-06	2.48e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.79e-06	2.47e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	1.77e-06	2.45e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.77e-06	2.44e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.77e-06	2.44e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—ALB—type 2 diabetes mellitus	1.75e-06	2.42e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.75e-06	2.41e-05	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.74e-06	2.4e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.73e-06	2.39e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.73e-06	2.39e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	1.72e-06	2.38e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.72e-06	2.37e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.71e-06	2.36e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.7e-06	2.35e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.7e-06	2.34e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.7e-06	2.34e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3R1—type 2 diabetes mellitus	1.68e-06	2.31e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—NOS3—type 2 diabetes mellitus	1.68e-06	2.31e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	1.67e-06	2.31e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.67e-06	2.31e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.66e-06	2.29e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	1.65e-06	2.28e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—SRC—type 2 diabetes mellitus	1.65e-06	2.27e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	1.64e-06	2.27e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.63e-06	2.24e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.62e-06	2.24e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—SRC—type 2 diabetes mellitus	1.61e-06	2.23e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	1.61e-06	2.22e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.61e-06	2.22e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.6e-06	2.21e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	1.6e-06	2.21e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.59e-06	2.2e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	1.58e-06	2.18e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	1.58e-06	2.18e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.58e-06	2.18e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.57e-06	2.17e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	1.56e-06	2.16e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	1.54e-06	2.13e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PTGS2—type 2 diabetes mellitus	1.53e-06	2.12e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—SRC—type 2 diabetes mellitus	1.5e-06	2.07e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	1.48e-06	2.04e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.47e-06	2.03e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.46e-06	2.01e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	1.45e-06	2e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	1.44e-06	1.99e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.44e-06	1.99e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.44e-06	1.99e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.41e-06	1.95e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—AKT1—type 2 diabetes mellitus	1.41e-06	1.95e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	1.41e-06	1.94e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	1.38e-06	1.91e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	1.38e-06	1.9e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	1.36e-06	1.88e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.34e-06	1.85e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.31e-06	1.81e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IL6—type 2 diabetes mellitus	1.28e-06	1.77e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IL6—type 2 diabetes mellitus	1.28e-06	1.76e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IL6—type 2 diabetes mellitus	1.22e-06	1.69e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	1.2e-06	1.66e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.18e-06	1.64e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.18e-06	1.63e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	1.18e-06	1.62e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.13e-06	1.56e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—AKT1—type 2 diabetes mellitus	1.11e-06	1.54e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IL6—type 2 diabetes mellitus	1.11e-06	1.53e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IL6—type 2 diabetes mellitus	1.09e-06	1.5e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	1.08e-06	1.49e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	1.03e-06	1.42e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	1.03e-06	1.42e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.02e-06	1.41e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—AKT1—type 2 diabetes mellitus	1.02e-06	1.41e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL6—type 2 diabetes mellitus	1.01e-06	1.39e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	1e-06	1.38e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	9.44e-07	1.3e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	9.31e-07	1.29e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—AKT1—type 2 diabetes mellitus	7.7e-07	1.06e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	7.26e-07	1e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	4.75e-07	6.55e-06	CbGpPWpGaD
